Eiger Biopharmaceuticals Stock Buy Hold or Sell Recommendation
| EIGR Stock | USD 2.05 0.44 27.33% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Eiger Biopharmaceuticals is 'Not Rated'. Macroaxis provides Eiger Biopharmaceutica buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding EIGR positions. The advice algorithm takes into account all of Eiger Biopharmaceutica's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Eiger Biopharmaceutica's buy or sell advice are summarized below:
Real Value 2.48 | Target Price 3 | Hype Value 2.35 | Market Value 2.05 | Naive Value 1.99 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Eiger Biopharmaceuticals given historical horizon and risk tolerance towards Eiger Biopharmaceutica. When Macroaxis issues a 'buy' or 'sell' recommendation for Eiger Biopharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Eiger |
Execute Eiger Biopharmaceutica Buy or Sell Advice
The Eiger recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Eiger Biopharmaceuticals. Macroaxis does not own or have any residual interests in Eiger Biopharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eiger Biopharmaceutica's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Eiger Biopharmaceutica Trading Alerts and Improvement Suggestions
| Eiger Biopharmaceutica is not yet fully synchronised with the market data | |
| Eiger Biopharmaceutica generated a negative expected return over the last 90 days | |
| Eiger Biopharmaceutica has high historical volatility and very poor performance | |
| Eiger Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 15.77 M. Net Loss for the year was (74.96 M) with profit before overhead, payroll, taxes, and interest of 11.65 M. | |
| Eiger Biopharmaceuticals currently holds about 141.79 M in cash with (74.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eiger Biopharmaceutica has a poor financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: EIGR, ADXN and BROG are among premarket gainers |
Eiger Biopharmaceutica current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Eiger analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Eiger analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Eiger Biopharmaceutica Returns Distribution Density
The distribution of Eiger Biopharmaceutica's historical returns is an attempt to chart the uncertainty of Eiger Biopharmaceutica's future price movements. The chart of the probability distribution of Eiger Biopharmaceutica daily returns describes the distribution of returns around its average expected value. We use Eiger Biopharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eiger Biopharmaceutica returns is essential to provide solid investment advice for Eiger Biopharmaceutica.
| Mean Return | -0.71 | Value At Risk | -11.17 | Potential Upside | 18.50 | Standard Deviation | 12.46 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eiger Biopharmaceutica historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Eiger Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eiger Biopharmaceutica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eiger Biopharmaceuticals backward and forwards among themselves. Eiger Biopharmaceutica's institutional investor refers to the entity that pools money to purchase Eiger Biopharmaceutica's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2023-12-31 | 81.1 K | Sequoia Financial Advisors Llc | 2023-12-31 | 63 K | Two Sigma Securities, Llc | 2023-12-31 | 57.2 K | Verition Fund Managegment, Llc | 2023-12-31 | 54.2 K | Bank Of America Corp | 2023-12-31 | 48.1 K | Tocqueville Asset Management L.p. | 2023-12-31 | 37.3 K | Charles Schwab Investment Management Inc | 2023-12-31 | 33.4 K | Townsquare Capital Llc | 2023-12-31 | 32.4 K | Dfpg Investments, Inc. | 2023-12-31 | 32.4 K | Ameriprise Financial Inc | 2023-12-31 | 7.5 M | Propel Bio Management Llc | 2023-12-31 | 4.4 M |
Eiger Biopharmaceutica Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (21.9M) | (10.5M) | (6.6M) | 3.6M | (358K) | (340.1K) | |
| Free Cash Flow | (64.1M) | (63.4M) | (120.1M) | (83.4M) | (74.8M) | (78.5M) | |
| Depreciation | 486K | 645K | 799K | 842K | 750K | 380.9K | |
| Other Non Cash Items | 949K | 1.0M | 713K | 4.1M | 1.5M | 1.4M | |
| Capital Expenditures | 475K | 258K | 48.7M | 340K | 234K | 222.3K | |
| Net Income | (70.3M) | (65.1M) | (33.9M) | (96.8M) | (75.0M) | (71.2M) | |
| End Period Cash Flow | 39.4M | 28.9M | 22.2M | 25.8M | 25.4M | 28.1M | |
| Investments | (16.0M) | (44.5M) | 15.0M | 10.0M | 74.2M | 77.9M | |
| Net Borrowings | 5.0M | 6.6M | (175K) | 5.4M | 4.9M | 4.4M | |
| Change To Netincome | 5.9M | 6.2M | 8.1M | 10.5M | 12.1M | 6.1M |
Note: Acquisition by Evan Loh of 12000 shares of Eiger Biopharmaceutica at 5.1 subject to Rule 16b-3 [view details]
Eiger Biopharmaceutica Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eiger . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Eiger Biopharmaceutica Buy or Sell Advice
When is the right time to buy or sell Eiger Biopharmaceuticals? Buying financial instruments such as Eiger Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 11.9M | 14.3M | 10.0M | 6.5M | Total Assets | 126.4M | 120.1M | 38.8M | 36.9M |
Use Investing Ideas to Build Portfolios
In addition to having Eiger Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cars Thematic Idea Now
Cars
Domestic and international companies involved in manufacturing and serving automobiles and trucks. The Cars theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Eiger Biopharmaceuticals information on this page should be used as a complementary analysis to other Eiger Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Eiger Stock analysis
When running Eiger Biopharmaceutica's price analysis, check to measure Eiger Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eiger Biopharmaceutica is operating at the current time. Most of Eiger Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Eiger Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eiger Biopharmaceutica's price. Additionally, you may evaluate how the addition of Eiger Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Eiger Biopharmaceutica's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eiger Biopharmaceutica. If investors know Eiger will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eiger Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (58.50) | Revenue Per Share 9.951 | Quarterly Revenue Growth (0.20) | Return On Assets (0.52) | Return On Equity (2.26) |
The market value of Eiger Biopharmaceuticals is measured differently than its book value, which is the value of Eiger that is recorded on the company's balance sheet. Investors also form their own opinion of Eiger Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is Eiger Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eiger Biopharmaceutica's market value can be influenced by many factors that don't directly affect Eiger Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eiger Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eiger Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eiger Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.